These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 19424516)

  • 41. HTR2C polymorphisms, olanzapine-induced weight gain and antipsychotic-induced metabolic syndrome in schizophrenia patients: a meta-analysis.
    Ma X; Maimaitirexiati T; Zhang R; Gui X; Zhang W; Xu G; Hu G
    Int J Psychiatry Clin Pract; 2014 Oct; 18(4):229-42. PubMed ID: 25152019
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Metabolic issues in psychotic disorders with the focus on first-episode patients: a review.
    Britvic D; Maric NP; Doknic M; Pekic S; Andric S; Jasovic-Gasic M; Popovic V
    Psychiatr Danub; 2013 Dec; 25(4):410-5. PubMed ID: 24247054
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Metabolic risk during antipsychotic treatment in patients with schizophrenia].
    Rzewuska M
    Psychiatr Pol; 2007; 41(4):457-72. PubMed ID: 18046977
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Metabolic syndrome in female patients with schizophrenia treated with second generation antipsychotics: a 3-month follow-up.
    Medved V; Kuzman MR; Jovanovic N; Grubisin J; Kuzman T
    J Psychopharmacol; 2009 Nov; 23(8):915-22. PubMed ID: 18635691
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Metabolic side effects of antipsychotic drug treatment--pharmacological mechanisms.
    Reynolds GP; Kirk SL
    Pharmacol Ther; 2010 Jan; 125(1):169-79. PubMed ID: 19931306
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Metformin plus sibutramine for olanzapine-associated weight gain and metabolic dysfunction in schizophrenia: a 12-week double-blind, placebo-controlled pilot study.
    Baptista T; Uzcátegui E; Rangel N; El Fakih Y; Galeazzi T; Beaulieu S; de Baptista EA
    Psychiatry Res; 2008 May; 159(1-2):250-3. PubMed ID: 18374423
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Does antipsychotic polypharmacy increase the risk for metabolic syndrome?
    Correll CU; Frederickson AM; Kane JM; Manu P
    Schizophr Res; 2007 Jan; 89(1-3):91-100. PubMed ID: 17070017
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effects of atypical antipsychotics on weight and serum lipid levels.
    Meyer JM
    J Clin Psychiatry; 2001; 62 Suppl 27():27-34; discussion 40-1. PubMed ID: 11806486
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Dyslipidemia independent of body mass in antipsychotic-treated patients under real-life conditions.
    Birkenaes AB; Birkeland KI; Engh JA; Faerden A; Jonsdottir H; Ringen PA; Friis S; Opjordsmoen S; Andreassen OA
    J Clin Psychopharmacol; 2008 Apr; 28(2):132-7. PubMed ID: 18344722
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics: results of the CLAMORS Study.
    Bobes J; Arango C; Aranda P; Carmena R; Garcia-Garcia M; Rejas J;
    Schizophr Res; 2007 Feb; 90(1-3):162-73. PubMed ID: 17123783
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Metabolic syndrome with the atypical antipsychotics.
    Pramyothin P; Khaodhiar L
    Curr Opin Endocrinol Diabetes Obes; 2010 Oct; 17(5):460-6. PubMed ID: 20717020
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The clinical implications of weight gain in schizophrenia.
    Kurzthaler I; Fleischhacker WW
    J Clin Psychiatry; 2001; 62 Suppl 7():32-7. PubMed ID: 11346194
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The METEOR study: frequency of metabolic disorders in patients with schizophrenia. Focus on first and second generation and level of risk of antipsychotic drugs.
    Falissard B; Mauri M; Shaw K; Wetterling T; Doble A; Giudicelli A; De Hert M
    Int Clin Psychopharmacol; 2011 Nov; 26(6):291-302. PubMed ID: 21876442
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Metabolic issues in patients with severe mental illness.
    Citrome L; Blonde L; Damatarca C
    South Med J; 2005 Jul; 98(7):714-20. PubMed ID: 16108240
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Association of adiponectin and metabolic syndrome among patients taking atypical antipsychotics for schizophrenia: a cohort study.
    Bai YM; Chen TT; Yang WS; Chi YC; Lin CC; Liou YJ; Wang YC; Su TP; Chou P; Chen JY
    Schizophr Res; 2009 Jun; 111(1-3):1-8. PubMed ID: 19409756
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Description of a healthy lifestyle intervention for people with serious mental illness taking second-generation antipsychotics.
    Park T; Usher K; Foster K
    Int J Ment Health Nurs; 2011 Dec; 20(6):428-37. PubMed ID: 21564457
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The genetic association of FTO variants with metabolic traits in patients with schizophrenia may be modified by antipsychotics.
    Huang MC; Kao CF; Chiu CC; Kuo PH; Chen PY; Lu ML; Chen CH
    J Clin Psychopharmacol; 2014 Feb; 34(1):162-5. PubMed ID: 24346748
    [No Abstract]   [Full Text] [Related]  

  • 58. Metformin for metabolic dysregulation in schizophrenic patients treated with olanzapine.
    Chen CH; Chiu CC; Huang MC; Wu TH; Liu HC; Lu ML
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 May; 32(4):925-31. PubMed ID: 18082302
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prevalence of obesity, glucose homeostasis disorders and metabolic syndrome in psychiatric patients taking typical or atypical antipsychotic drugs: a cross-sectional study.
    Mackin P; Watkinson HM; Young AH
    Diabetologia; 2005 Feb; 48(2):215-21. PubMed ID: 15688206
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficacy of metformin and topiramate in prevention and treatment of second-generation antipsychotic-induced weight gain.
    Ellinger LK; Ipema HJ; Stachnik JM
    Ann Pharmacother; 2010 Apr; 44(4):668-79. PubMed ID: 20233913
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.